Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cell Therapy in Older Adults with AML
NCT01639456Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Oct 2013
- Primary completion
- Jan 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of haploidentical natural killer cells in acute myeloid leukemia (AML), sponsored by Masonic Cancer Center. Planned start Oct 2013; status: withdrawn.
02
Drugs
haploidentical natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01639456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01639456.